Search
lesinurad (Zurampic)
Indications:
- treatment of gout
- for use in conjunction with xanthine oxidase inhibitor
- for patients who have not achieved serum uric acid targets with xanthine oxidase inhibitor (allopurinol or febuxostat) alone [1]
Contraindications:
- severe renal impairment, ESRD
Dosage:
- 200 mg PO QD
- in clinical trial, administered with food
Pharmacokinetics:
- absorption 100%
- 98% protein bound, mainly to albumin
- 1/2 life 5 hours
- does not accumulate with multiple doses
- plasma levels not significantly altered by renal insufficiency or hepatic insufficiency
Adverse effects:
- headache, influenza, increased blood creatinine, and gastroesophageal reflux disease [1]
* boxed warning: risk for acute renal failure, higher when used alone [1]
Mechanism of action:
- inhibits the function of URAT1 involved in reabsorption of uric acid in the renal tubules
General
hypouricemic agent
enzyme inhibitor
carboxylate
Database Correlations
PUBCHEM correlations
References
- FDA News Release. December 22, 2015
FDA approves Zurampic to treat high blood uric acid levels
associated with gout.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478791.htm
- lesinurad (Zurampic) prescribing information
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf
Component-of
allopurinol/lesinurad (Duzallo)